Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021

Background:Sacubitril/valsartan has been approved for the treatment of heart failure (HF) patients with reduced ejection fraction; since then, it gradually became a new star drug in the therapy of HF. Nevertheless, the effectiveness of sacubitril/valsartan remains under investigation. Thus far, only a few bibliometric studies have systematically analyzed the application of sacubitril/valsartan.Methods:Publications on sacubitril/valsartan were retrieved from the Web of Science Core Collection on April 29, 2021. Data were analyzed using Microsoft Excel 2019 (Redmond, WA), VOS viewer (Redmond, WA), and Cite Space V (Drexel University, Philadelphia, PA).Results:A total of 1309 publications on sacubitril/valsartan published from 1995 to 2021 were retrieved. The number of publications regarding sacubitril/valsartan increased sharply in the last 6 years (2015–2021), and American scholars authored >40% of those publications. Most were published in the European Journal of Heart Failure, the United States was the bellwether with a solid academic reputation in this area. Solomon published the highest number of related articles and was the most frequently cited author. “Heart failure” was the leading research hotspot. The keywords, “inflammation,” “fibrosis,” and “oxidative stress” appeared most recently as research fronts.Conclusions:Research attention should be focused on clinical trial outcomes. Considering its effectiveness in HF, the mechanisms and further applications of sacubitril/valsartan may become research hotspots in the future and should be closely examined.     

叶景华运用宁神合剂治疗失眠症的经验

失眠症是指睡眠不足或睡眠质量不好的病症,表现为入睡困难,夜间多次觉醒,不能再入睡,清晨早醒,睡醒后不能恢复精力.中医称为不寐,是指脏腑机能紊乱,气血亏虚,阴阳失调,而不能获得正常的睡眠.常伴有头痛,头昏,心悸,健忘,多梦等症.各系统和实验室检查常无异常.在古代文献中亦有称为"不得卧"、"不得眠"以及"目不瞑"等.     

鼻咽癌中国1992、2008分期和国际抗癌联盟2010分期标准的比较研究

目的 比较鼻咽癌中国1992、2008分期和国际抗癌联盟(UICC)2010分期标准之间的一致性,评价它们在预测鼻咽癌放疗疗效中的价值.方法 回顾分析2000-2005年间347例无远处转移的初治鼻咽癌患者临床资料,对每例患者分别用中国1992、2008和UICC2010分期标准进行T、N和临床分期.采用Kappa法分析3种分期标准间各期病例数分布的一致性.采用Kaplan-Meier法分别计算3种分期标准的5年总生存率、局部无复发和无远处转移生存率,并用Logrank检验其差异.结果 中国2008分期和UICC 2010分期标准之间的临床分期、T和N分期的病例构成比例的一致性均优于它们各自与1992分期之间的比较,Kappa值分别为0.700、0.881和0.722.3种分期标准下各临床分期的总生存曲线比较只发现Ⅲ与Ⅳ期间的不同,其中2008分期和UICC2010分期标准下Ⅲ与Ⅳ期间的不同(χ2=4.48,P=0.034和χ2=8.88,P=0.003),而1992分期则相似(χ2=0.40,P=0.526).3种分期标准的局部无复发生存率各T1与T2和T2与T3及T3与T4期间的比较均相似(χ2=1.85、0.53、0.50,P=0.174、0.467、0.479和χ2=1.25、2.10、1.99,P=0.264、0.148、0.159及χ2=0.77、0.60、0.87,P=0.381、0.441、0.350).在3种分期标准的各期无远处转移生存率中,1992分期标准的N0与N1、N1与N2、N2与N3间均相似(χ2=3.71、3.11、2.01,P=0.054、0.078、0.156),2008分期标准的N1与N2、N2与N3间不同(χ2=10.49、5.06,P=0.001、0.024);UICC 2010分期标准中仅N1与N2间不同(χ2=7.73,P=0.005).结论 中国2008分期和UICC2010分期标准对鼻咽癌放疗疗效的预测价值相近,且均优于1992分期.

Abstract：

Objective To compare the agreement among Chinese 1992, 2008 and UICC 2010 staging systems of nasopharyngeal carcinoma (NPC) and evaluate their predictive value of radiotherapeutic prognosis.Methods 347 NPC patients without distant metastasis treated in our hospital from 2000 to 2005 were retrospectively analyzed.Every patient was categorized into T, N, and clinical stage by Chinese 1992, 2008 and UICC 2010 staging systems, respectively.Kappa value was used to evaluate the agreement among three systems.Kaplan-Meier method was used to analyze the 5-year overall survival (OS), local-free survival (LFS) and distant metastasis-free survival (DMFS), the difference between subgroup was tested by Logrank.Results The agreement of clinical stage, T and N stage between Chinese 2008 and UICC 2010 staging system was better than that of them compared to 1992 staging system, Kappa value were 0.700、0.881 and 0.722.The agreement of T stage was better than N and clinical stage among these three staging system.The difference of OS between stageⅢ and stage Ⅳ was significant in Chinese 2008 and UICC 2010 staging system (χ2=4.48,P=0.034;χ2=8.88,P=0.003), and with no different in 1992 staging system (χ2=0.40,P=0.526).There was no significant difference of LFS between T1 and T2,T2 and T3,T3 and T4 in all staging systems (χ2=1.85,0.53,0.50,P=0.174,0.467,0.479;χ2=1.25,2.10,1.99,P=0.264,0.148,0.159;χ2=0.77,0.60,0.87, P=0.381,0.441,0.350).There were no significant differencesin 1992 staging system, while there was significant differences of DMFS between N1 and N2, N2 and N3 in 2008 stage system, N1 and N2 in UICC 2010 stage system.Conclusions The predictive value of Chinese 2008 and UICC 2010 staging system for prognosis were similar, and were better than that of 1992 staging system in NPC.     

PGE2对非小细胞肺癌组织浸润T淋巴细胞中PD-1表达的影响及其机制

目的:探讨程序性死亡受体1(PD-1)在非小细胞肺癌(NSCLC)组织浸润CD4+和CD8+T淋巴细胞中的表达情况,阐明前列腺素E2(PGE2)对PD-1的影响及其相关机制.方法:选取确诊的75例NSCLC患者作为研究对象,根据国际抗癌联盟(UICC)颁布的NSCLC TNM分期标准,将患者分为I～Ⅳ期.应用密度梯度离...     

APC介入治疗支气管结核的临床疗效探讨

目的探讨氩等离子体凝固(argon plasma coagulation,APC)介入治疗支气管结核的临床疗效。方法对40例确诊支气管结核的患者实施经可弯曲电子支气管镜氩气刀介入治疗,并观察其疗效。结果40例治疗1～4次,平均1.9次,经支气管镜复查,显效30例,占75%;有效10例,占25%;总有效率100%。不良反应:治疗中22例有轻微刺激性呛咳,4例感觉局部烧灼痛,未发生支气管壁坏死、穿孔、气胸、纵隔气肿等并发症。结论APC介入治疗支气管结核,在解除支气管阻塞、加速病灶的吸收及组织再生和修复方面疗效确切,痰菌阴转率及肺不张治愈率均较高,能缓解支气管狭窄后遗症,安全性高,不良反应小,有较好的临床应用价值。     

经胸超声心动图在经心导管封堵小儿房问隔缺损中的应用

目的探讨经胸超声心动图(TTE)在经心导管封堵小儿房间隔缺损(ASD)中的应用价值.方法TTE多个切面测量46例ASD最大直径,ASD部位及周围关系,术中TTE测量ASD球囊伸展径并与X线所测球囊伸展径比较,选择Amplatzer ASD封堵器的型号、引导封堵器的放置及疗效评价.结果46例经心导管封堵的ASD中40例封堵成功,6例因术中严重心律失常、Amplatzer ASD封堵器意外脱落、ASD太大和左房长径不足以及ASD距下腔静脉太近而未能封堵成功.TTE测ASD最大径(1.43±0.68)cm与X线所测球囊伸展径(1.66±0.82)cm高度相关,(r=0.89,P<0.01),TTE术中测球囊伸展径(1.78±0.85)cm与X线测球囊伸展径高度相关,(r=0.98,P<0.01).结论TTE能很好显示小儿ASD大小、部位及其周围关系,方法简便,无痛苦,在经导管封堵小儿ASD中具有重要作用.     

论绍派伤寒的学术创新与薪传

《伤寒论》代表了前一时期的外感病总论,温病学代表了后一时期的外感病总论,在伤寒与温病的论争中,绍派伤寒又代表了对外感病认识进一步深化的一个时期。绍派伤寒的寒温一统说可谓异帜独张,它与温病学派的主张存在多方面的不同,并在不断的学术争鸣中得到完善。     

竹红菌甲素敏化E．coli菌体蛋白光氧化反应及机制

本工作利用ＳＤＳ聚丙烯酰胺胶电泳技术分析了甲素对Ｅ．ｃｏｌｉ菌体蛋白光氧化的敏化作用。实验结果表明，甲素结合光照可引起菌体蛋白降解及交联。甲素敏化菌体蛋白光氧化反应可放单线态氧淬灭剂──ＮａＮ３抑制，但不被各种氧自由基、羟自由基抑制剂所阻断，提示甲素敏化的菌体蛋白光氧化反应属Ⅱ型机制。     

经导管射频消融治疗室性心律失常的疗效观察

目的 探讨经导管射频消融治疗特发性室性心动过速及频发室性期前收缩的疗效及安全性.方法 141例特发室性心动过速及频发室性期前收缩患者(男80例,女61例)采用激动顺序标测和(或)起搏标测方法行导管射频消融治疗.结果 消融成功128例,成功率为90.8%,起源于右室流出道的室性心动过速或室性期前收缩消融成功率为92.0%.20例患者行消融前后的Hoher检查,术前平均(21 824±12 769)次/24 h,术后平均(1 548±2 926)次/24 h,二者间差异有统计学意义(P<0.001).随访3～36个月,10例复发并全部再次消融成功.无并发症发生.结论 导管射频消融治疗症状严重且药物治疗无效的特发性室性心动过速或频发室性期前收缩是安全、有效、可行的方法.